Floxuridine (FUdR)

An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Also Known As:

Networked: 690 relevant articles (63 outcomes, 117 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kim, Hye-Sook: 13 articles (11/2020 - 01/2002)
2.	Sato, Akira: 13 articles (11/2020 - 01/2006)
3.	Wataya, Yusuke: 13 articles (11/2020 - 01/2002)
4.	Xiang, Yang: 12 articles (12/2021 - 08/2003)
5.	Hiramoto, Akiko: 12 articles (11/2020 - 01/2006)
6.	Jarnagin, William R: 10 articles (01/2022 - 07/2009)
7.	Kemeny, Nancy E: 9 articles (01/2022 - 05/2009)
8.	Satake, Akito: 9 articles (01/2016 - 01/2006)
9.	D'Angelica, Michael I: 8 articles (01/2022 - 01/2011)
10.	Fong, Yuman: 7 articles (02/2013 - 08/2005)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 02/01/1999 - "Improved results with high response rates have been reported after development of intra-arterial (i.a.) long-term regimens with FUdR in patients with colorectal liver metastases using implantable pumps and ports. " 02/01/1992 - "In contrast, delayed HA FUdR infusion controlled hepatic metastases (P = 0.04) and improved survival (P < 0.05)." 01/01/2021 - "This phase II trial randomized patients with KRAS wild-type resected colorectal liver metastases to adjuvant HAI FUDR + SYS FOLFIRI +/- Pmab (NCT01312857). " 06/01/2014 - "The 1-, 3-, and 5-year survival rates after metastasis were 97%, 49%, and 26% for the ablation group, and 72%, 24%, and 24% for the FUDR group, respectively. " 06/01/2014 - "Patients in the two groups were matched by sex, age, number of metastases, and calendar year of RFA or FUDR. "
2.	Colorectal Neoplasms (Colorectal Cancer) 12/01/1990 - "In this study, the direct cytotoxic effect of FUdR was measured on ten metastatic and two primary-site colorectal carcinomas in a primary culture assay system. " 08/01/1990 - "Based on these data, we cannot recommend treatment with intra-arterial floxuridine as given in this study for metastatic colorectal cancer to the liver." 11/01/1989 - "A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial." 01/01/2017 - "Pretreatment 5-FUDR and MTHFR A1298T or C677T, TSER, and DPYD gene polymorphisms were characterized in stages II-III colorectal cancer patients. " 06/01/2016 - "Transcriptome profiling identifies genes and pathways deregulated upon floxuridine treatment in colorectal cancer cells harboring GOF mutant p53."
3.	Neoplasms (Cancer) 08/01/1991 - "More importantly, the tumor/liver ratio of FUDR uptake was significantly greater in the HA/A-II group (3.40) than that in the HA without A-II (0.98) group (P less than 0.001). " 08/01/1991 - "Hepatic artery infusions, both with and without A-II, resulted in a significantly greater tumor uptake of FUDR than the iv infusions (P less than 0.001). " 01/01/1989 - "Hepatic artery infusion resulted in a significantly improved tumor-to-liver ratio of FUDR uptake (p less than 0.001). " 11/01/1986 - "A pilot study was designed to evaluate the efficacy of high-dose FUDR administered through the hepatic artery for the treatment of cancer involving the liver. " 01/01/1986 - "A significant reduction of tumor growth was observed only after continuous infusion of FUDR via the hepatic artery. "
4.	Renal Cell Carcinoma (Grawitz Tumor) 05/15/1995 - "Continuous infusion of 2'-deoxy-5-fluorouridine (FUdR) has shown promise in its activity against metastatic renal cell carcinoma. " 08/01/1996 - "In this study FUDR + alpha 2b-IFN demonstrated interesting activity in metastatic renal cell carcinoma, showing promise also in patients with unfavourable prognostic characteristics. " 08/01/1996 - "The main purpose of this phase II study was to assess the activity and toxic effects of a combination of FUDR and alpha 2b-IFN in metastatic renal cell carcinoma. " 01/01/1995 - "The CADD-Micro System (Sims Deltec, St. Paul, MN) was formally evaluated in patients with metastatic renal cell cancer, participating in a phase-III study comparing a 2-week circadian versus flat infusion of FUDR. " 06/01/1993 - "A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma."
5.	Trophoblastic Neoplasms (Trophoblastic Tumor) 06/01/2004 - "Floxuridine-containing regimens in the treatment of gestational trophoblastic tumor." 08/01/2003 - "[Floxuridine-containing regime in the treatment of gestational trophoblastic tumor]." 08/01/2003 - "Seventy-four patients with gestational trophoblastic tumors (GTT), 47 invasive mole and 27 choriocarcinoma, were treated with FUDR-containing regime. " 06/01/2004 - "To analyze the efficacy of floxuridine (FUDR)-containing regimens in the treatment of gestational trophoblastic tumor (GTT). " 08/01/2003 - "To analyse the efficacy of the floxuridine (FUDR)-containing regime (single agent or in combination) in the treatment of gestational trophoblastic tumor. "

Related Drugs and Biologics

1.	Floxuridine (FUdR)
2.	Fluorouracil (Carac)
3.	Irinotecan (Camptosar)
4.	Mitomycin (Mitomycin-C)
5.	Oxaliplatin (Eloxatin)
6.	Leucovorin (Folinic Acid)
7.	Dexamethasone (Maxidex)
8.	5-fluoro-2'-deoxyuridine
9.	Etoposide (VP 16)
10.	Vincristine (Oncovin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Catheters
4.	Infusion Pumps (Infusion Pump)
5.	Laparotomy